These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28736525)

  • 1. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.
    Mohamed FE; Al-Gazali L; Al-Jasmi F; Ali BR
    Front Pharmacol; 2017; 8():448. PubMed ID: 28736525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFEB regulates lysosomal proteostasis.
    Song W; Wang F; Savini M; Ake A; di Ronza A; Sardiello M; Segatori L
    Hum Mol Genet; 2013 May; 22(10):1994-2009. PubMed ID: 23393155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
    Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease.
    Seemann S; Ernst M; Cimmaruta C; Struckmann S; Cozma C; Koczan D; Knospe AM; Haake LR; Citro V; Bräuer AU; Andreotti G; Cubellis MV; Fuellen G; Hermann A; Giese AK; Rolfs A; Lukas J
    Biochem J; 2020 Jan; 477(2):359-380. PubMed ID: 31899485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
    Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
    Macauley SL
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical and biological approaches synergize to ameliorate protein-folding diseases.
    Mu TW; Ong DS; Wang YJ; Balch WE; Yates JR; Segatori L; Kelly JW
    Cell; 2008 Sep; 134(5):769-81. PubMed ID: 18775310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of homeostasis in lysosomal storage disorders.
    Segatori L
    IUBMB Life; 2014 Jul; 66(7):472-7. PubMed ID: 25044960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
    Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
    Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for lysosomal storage disorders: developing insights.
    van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ
    Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.
    Muntau AC; Leandro J; Staudigl M; Mayer F; Gersting SW
    J Inherit Metab Dis; 2014 Jul; 37(4):505-23. PubMed ID: 24687294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.